What’s next?

  • We’re establishing our commercial-scale GMP facility in the US.
  • We will have multiple 2000L manufacturing suites for clinical and commercial manufacturing.
  • We’re increasing the scale in our GMP microbial GMP facility to 200L.
  • We’re registering Denosumab in the US and the EU, Teriparatide in the EU and Liraglutide in the US.